My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
9.410
+0.050 (+0.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prothena Corporation plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
May 27, 2025
Via
Benzinga
These stocks are moving in today's after hours session
May 26, 2025
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
May 23, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
A Look Ahead: Prothena Corp's Earnings Forecast
May 07, 2025
Via
Benzinga
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
Top movers in Friday's after hours session
May 23, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
May 23, 2025
From
Prothena Corporation plc
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
May 16, 2025
Via
Benzinga
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
February 07, 2025
Via
Benzinga
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
December 20, 2024
Via
Benzinga
Expert Ratings For Prothena Corp
November 13, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Prothena Corp Stock
May 09, 2025
Via
Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
May 09, 2025
Via
Benzinga
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report First Quarter 2025 Financial Results on May 8
May 01, 2025
From
Prothena Corporation plc
Via
Business Wire
Earnings Preview For Prothena Corp
November 11, 2024
Via
Benzinga
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
February 26, 2025
Via
Benzinga
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
February 20, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
February 13, 2025
From
Prothena Corporation plc
Via
Business Wire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
January 28, 2025
Via
Benzinga
Prothena Announces Board of Directors Update
December 30, 2024
From
Prothena Corporation plc
Via
Business Wire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
December 20, 2024
Via
Benzinga
Topics
Stocks
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
December 19, 2024
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients.
Via
Investor's Business Daily
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
December 19, 2024
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses.
Via
Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
December 19, 2024
Via
Benzinga
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
December 19, 2024
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
From
Prothena Corporation plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.